Home > Press release

 

 

ARCHIVE PRESS RELEASE
Chiesi Group Forges Alliance with Karolinska Institutet to Tackle Urgent Health Challenges
Chiesi and Gossamer Bio Announce Transformative Global Collaboration to Develop and Commercialize Seralutinib in Pulmonary Arterial Hypertension and Other Respiratory Indications
Chiesi Group's 2023 Revenue Surpasses €3 Billion Mark, Reflecting 10% Growth Year-on-Year (+12% @CER), Underlining Commitment to Innovative, Sustainable Practices
Chiesi Carbon Minimal Inhalers reach new milestone with clinical phase III initiation
Chiesi Group: a new supplementary labor agreement in Italy puts people and their needs first
Chiesi Group announces the passing of Honorary President Dr. Paolo Chiesi (1940-2024)
PAST, PRESENT, FUTURE
Chiesi Group and Oak Hill Bio announce License and Development Agreement to develop, manufacture, and commercialize OHB-607, a potentially transformative neonatal therapy
Chiesi Global Rare Diseases Receives FDA Approval for FILSUVEZ® (birch triterpenes) topical gel for the Treatment of Epidermolysis Bullosa
Chiesi was awarded the 59° Oscar di Bilancio for the Benefit Corporation category